Abeona Therapeutics (ABEO) News Today $6.41 +0.05 (+0.79%) (As of 10/31/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 Time Period Abeona Therapeutics (NASDAQ:ABEO) Receives "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $15.00 price target on shares of Abeona Therapeutics in a report on Thursday.October 31 at 8:37 AM | marketbeat.comAbeona Therapeutics' (ABEO) Overweight Rating Reiterated at Cantor FitzgeraldOctober 30 at 5:07 AM | americanbankingnews.comAbeona Therapeutics completes Pz-cel BLA resubmission to U.S. FDAOctober 29 at 6:34 PM | markets.businessinsider.comAbeona Therapeutics (NASDAQ:ABEO) Stock Rating Reaffirmed by Cantor FitzgeraldCantor Fitzgerald restated an "overweight" rating and issued a $18.00 price target on shares of Abeona Therapeutics in a research note on Tuesday.October 29 at 12:30 PM | marketbeat.comAbeona Therapeutics® Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug AdministrationOctober 29 at 7:30 AM | globenewswire.comRosalind Advisors, Inc. Expands Stake in Myomo IncOctober 19, 2024 | finance.yahoo.comAbeona Therapeutics (NASDAQ:ABEO) Share Price Crosses Above 50-Day Moving Average - What's Next?Abeona Therapeutics (NASDAQ:ABEO) Share Price Crosses Above Fifty Day Moving Average - Here's What HappenedOctober 11, 2024 | marketbeat.comAbeona Therapeutics Inc (ABEO) Q2 2024 Earnings Call Highlights: Strong Financial Performance ...October 10, 2024 | finance.yahoo.comAbeona Therapeutics Targets RDEB Market With Promising Pz-cel TherapyOctober 3, 2024 | seekingalpha.comRenaissance Technologies LLC Grows Stake in Abeona Therapeutics Inc (NASDAQ:ABEO)Renaissance Technologies LLC grew its stake in shares of Abeona Therapeutics Inc (NASDAQ:ABEO - Free Report) by 581.6% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 503,293 shares of the biopharmaceutical company's stock after buyinOctober 3, 2024 | marketbeat.comAbeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 1, 2024 | globenewswire.comAbeona Therapeutics Inc (NASDAQ:ABEO) Sees Significant Drop in Short InterestAbeona Therapeutics Inc (NASDAQ:ABEO - Get Free Report) was the recipient of a significant decrease in short interest in September. As of September 15th, there was short interest totalling 2,630,000 shares, a decrease of 7.4% from the August 31st total of 2,840,000 shares. Currently, 6.7% of the shares of the stock are short sold. Based on an average daily trading volume, of 301,300 shares, the short-interest ratio is currently 8.7 days.September 29, 2024 | marketbeat.comAbeona Therapeutics' (ABEO) "Overweight" Rating Reiterated at Cantor FitzgeraldCantor Fitzgerald reissued an "overweight" rating and set a $18.00 price target on shares of Abeona Therapeutics in a research note on Friday.September 20, 2024 | marketbeat.comSimplify Asset Management Inc. Makes New $1.73 Million Investment in Abeona Therapeutics Inc (NASDAQ:ABEO)Simplify Asset Management Inc. bought a new stake in Abeona Therapeutics Inc (NASDAQ:ABEO - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 408,584 shares of the biopharmaceutical company's stock, valued at aSeptember 20, 2024 | marketbeat.comAbeona Therapeutics Inc (NASDAQ:ABEO) Sees Large Decrease in Short InterestAbeona Therapeutics Inc (NASDAQ:ABEO - Get Free Report) was the target of a significant decrease in short interest during the month of August. As of August 31st, there was short interest totalling 2,840,000 shares, a decrease of 6.3% from the August 15th total of 3,030,000 shares. Currently, 7.3% of the shares of the company are sold short. Based on an average trading volume of 348,000 shares, the short-interest ratio is currently 8.2 days.September 18, 2024 | marketbeat.comAbeona Therapeutics (NASDAQ:ABEO) Stock Passes Below 200-Day Moving Average of $5.49Abeona Therapeutics (NASDAQ:ABEO) Shares Pass Below 200-Day Moving Average of $5.49September 18, 2024 | marketbeat.comAbeona Therapeutics (NASDAQ:ABEO) Shares Pass Above Fifty Day Moving Average of $5.08Abeona Therapeutics (NASDAQ:ABEO) Share Price Crosses Above 50-Day Moving Average of $5.08September 10, 2024 | marketbeat.comAbeona Therapeutics® Announces Participation in Upcoming Investor ConferencesSeptember 3, 2024 | globenewswire.comStockNews.com Downgrades Abeona Therapeutics (NASDAQ:ABEO) to SellStockNews.com lowered Abeona Therapeutics from a "hold" rating to a "sell" rating in a research note on Monday.September 2, 2024 | marketbeat.comAbeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 2, 2024 | globenewswire.comResearch Analysts Offer Predictions for Abeona Therapeutics Inc's FY2024 Earnings (NASDAQ:ABEO)Abeona Therapeutics Inc (NASDAQ:ABEO - Free Report) - Stock analysts at Zacks Small Cap raised their FY2024 earnings estimates for Abeona Therapeutics in a report released on Wednesday, August 14th. Zacks Small Cap analyst D. Bautz now forecasts that the biopharmaceutical company will earn ($1.33August 19, 2024 | marketbeat.comQ3 2024 Earnings Estimate for Abeona Therapeutics Inc Issued By HC Wainwright (NASDAQ:ABEO)Abeona Therapeutics Inc (NASDAQ:ABEO - Free Report) - Equities researchers at HC Wainwright cut their Q3 2024 earnings per share estimates for shares of Abeona Therapeutics in a research note issued to investors on Wednesday, August 14th. HC Wainwright analyst R. Selvaraju now expects that the biAugust 16, 2024 | marketbeat.comABEO: Type A Meeting with FDA Concluded; BLA Submission on Track for 2H24…August 15, 2024 | msn.comBuy Rating on Abeona Therapeutics Bolstered by Positive Medicare Decisions and FDA Approval ProgressAugust 15, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Abeona Therapeutics (ABEO), Cyclacel Pharmaceuticals (CYCC) and Cardinal Health (CAH)August 15, 2024 | markets.businessinsider.comAbeona Therapeutics (NASDAQ:ABEO) Receives Buy Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $15.00 price target on shares of Abeona Therapeutics in a research report on Wednesday.August 14, 2024 | marketbeat.comAbeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of DirectorsAugust 14, 2024 | globenewswire.comAbeona Therapeutics (NASDAQ:ABEO) Upgraded to "Hold" by StockNews.comStockNews.com upgraded Abeona Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday.August 13, 2024 | marketbeat.comAbeona Therapeutics® Announces Favorable Medicare Reimbursement Decisions for Pz-celAugust 13, 2024 | globenewswire.comAbeona Therapeutics® Reports Second Quarter 2024 Financial Results and Concludes Type A Meeting with FDA to Align on Upcoming Pz-cel BLA ResubmissionAugust 12, 2024 | globenewswire.comAbeona Therapeutics (NASDAQ:ABEO) Shares Pass Below 200-Day Moving Average of $5.58Abeona Therapeutics (NASDAQ:ABEO) Stock Passes Below Two Hundred Day Moving Average of $5.58August 7, 2024 | marketbeat.com0H7R.IL,0P0001H727,0 (0H7R.IL)August 4, 2024 | uk.finance.yahoo.comAbeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 1, 2024 | globenewswire.comInstitutional investors own a significant stake of 39% in Abeona Therapeutics Inc. (NASDAQ:ABEO)July 21, 2024 | finance.yahoo.comAbeona Therapeutics and Beacon Therapeutics Announce Non-Exclusive Agreement for Beacon to Evaluate Therapeutic Potential of Abeona's Patented AAV204 Capsid for Select Ophthalmology IndicationsJuly 11, 2024 | globenewswire.comAbeona Therapeutics to Present at the Stifel Virtual Cell Therapy ForumJuly 8, 2024 | globenewswire.comAbeona Therapeutics Inc (NASDAQ:ABEO) to Post Q3 2024 Earnings of ($0.36) Per Share, HC Wainwright ForecastsAbeona Therapeutics Inc (NASDAQ:ABEO - Free Report) - Stock analysts at HC Wainwright issued their Q3 2024 EPS estimates for Abeona Therapeutics in a research report issued on Wednesday, July 3rd. HC Wainwright analyst R. Selvaraju forecasts that the biopharmaceutical company will post earnings pJuly 8, 2024 | marketbeat.comAbeona Therapeutics (NASDAQ:ABEO) Now Covered by HC WainwrightHC Wainwright began coverage on shares of Abeona Therapeutics in a research report on Wednesday. They issued a "buy" rating and a $15.00 price target for the company.July 3, 2024 | marketbeat.comAbeona Therapeutics Inc (NASDAQ:ABEO) Short Interest Down 24.2% in MayAbeona Therapeutics Inc (NASDAQ:ABEO - Get Free Report) was the recipient of a significant decrease in short interest during the month of May. As of May 31st, there was short interest totalling 2,290,000 shares, a decrease of 24.2% from the May 15th total of 3,020,000 shares. Approximately 5.8% of the company's stock are sold short. Based on an average trading volume of 712,100 shares, the short-interest ratio is currently 3.2 days.June 14, 2024 | marketbeat.comAbeona Therapeutics (NASDAQ:ABEO) Shares Cross Below 50-Day Moving Average of $5.27Abeona Therapeutics (NASDAQ:ABEO) Share Price Passes Below 50-Day Moving Average of $5.27June 11, 2024 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEOJune 7, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEOJune 5, 2024 | globenewswire.comAbeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 3, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEOMay 30, 2024 | prnewswire.comAbeona Therapeutics (NASDAQ:ABEO) Coverage Initiated by Analysts at Stifel NicolausStifel Nicolaus began coverage on shares of Abeona Therapeutics in a research report on Thursday. They set a "buy" rating and a $21.00 target price for the company.May 30, 2024 | marketbeat.comQ2 2024 EPS Estimates for Abeona Therapeutics Inc (NASDAQ:ABEO) Lifted by AnalystAbeona Therapeutics Inc (NASDAQ:ABEO - Free Report) - Zacks Small Cap raised their Q2 2024 earnings per share estimates for Abeona Therapeutics in a research report issued on Tuesday, May 28th. Zacks Small Cap analyst D. Bautz now forecasts that the biopharmaceutical company will post earnings ofMay 30, 2024 | marketbeat.comABEO: BLA Resubmission in 2H24May 28, 2024 | msn.comAbeona Therapeutics to Present at the Jefferies Global Healthcare ConferenceMay 28, 2024 | globenewswire.comAIGH Capital Management LLC Has $3.95 Million Holdings in Abeona Therapeutics Inc (NASDAQ:ABEO)AIGH Capital Management LLC decreased its holdings in Abeona Therapeutics Inc (NASDAQ:ABEO - Free Report) by 30.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 787,769 shares of the biopharmaceutical company's stockMay 27, 2024 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEOMay 23, 2024 | prnewswire.com Get Abeona Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ABEO and its competitors with MarketBeat's FREE daily newsletter. Email Address Banking failure dead ahead (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soon Click here to watch it now. ABEO Media Mentions By Week ABEO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ABEO News Sentiment▼0.210.68▲Average Medical News Sentiment ABEO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ABEO Articles This Week▼82▲ABEO Articles Average Week Get Abeona Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ABEO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies uniQure News Voyager Therapeutics News Aclaris Therapeutics News Equillium News Lumos Pharma News REGENXBIO News OPKO Health News ArriVent BioPharma News Aurinia Pharmaceuticals News Evolus News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ABEO) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abeona Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Abeona Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
